Evidence map›Paper›PMID 41217458›Full record

ArticleWorld journal of urology2025

Robotic vs. open partial cytoreductive nephrectomy in metastatic renal cell carcinoma: adverse in-hospital outcomes.

Quynh Chi Le, Mattia Longoni, Andrea Marmiroli, Fabian Falkenbach, Calogero Catanzaro, Michele Nicolazzini, Federico Polverino, Jordan A Goyal, Fred Saad, Riccardo Schiavina and 8 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Quynh Chi LeCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. d.le@med.uni-frankfurt.de.
Mattia LongoniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Andrea MarmiroliCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Fabian FalkenbachCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Calogero CatanzaroCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Michele NicolazziniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Federico PolverinoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Jordan A GoyalCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Riccardo SchiavinaDepartment of Urology, St. Orsola-Malpighi Hospital, University of Bologn, Bologna, Italy.
Luca Fabio CarmignaniDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Alberto BrigantiDivision of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Nicola LongoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Markus GraefenMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Carlotta PalumboDivision of Urology, Department of Translational Medicine, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
Miriam TraumannDepartment of Urology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
Felix K-H ChunDepartment of Urology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo test for adverse in-hospital outcomes after robotic (RPCN) vs. open partial cytoreductive nephrectomy (OPCN).

methodsRPCN and OPCN patients were retrospectively identified within the National Inpatient Sample database (2008-2019). Propensity score matching (PSM, ratio 1:2) and multivariable logistic regression models (LRM) were used.

resultsOf 491 patients, 139 (28%) underwent RPCN vs. 352 (72%) OPCN. RPCN-rate increased from 4.2 to 42.5% over time (p < 0.001). RPCN patients exhibited similar age, comorbidity and race/ethnicity distribution relative to their OPCN counterparts. After 1:2 PSM, all 139 RPCN and 278 of 352 (79%) OPCN patients were included. Relative to OPCN, RPCN patients exhibited lower rates in four of 10 examined adverse in-hospital outcomes: intraoperative complications (< 3 vs. 9%, p = 0.02), pulmonary complications (6 vs. 14%, p = 0.02), blood transfusions (< 5 vs. 14%, p = 0.004) and exhibited shorter median length of stay (2 vs. 4 days, p < 0.001). In multivariable LRMs, RPCN independently predicted lower rates in the same four of 10 categories with odds ratio (OR) ranging from 0.17 to 0.34. Largest magnitude was recorded in shorter length of stay (OR 0.17, p < 0.001), followed by intraoperative complications (OR 0.24, p = 0.02), use of blood transfusions (OR 0.25, p = 0.003) and pulmonary complications (OR 0.34, p = 0.01). No differences in in-hospital mortality were recorded.

conclusionRates of RPCN has increased exponentially over time (4.2 to 42.5%). Relative to OPCN, RPCN is associated with fewer adverse in-hospital outcomes and shorter hospital stay. However, no differences regarding in-hospital mortality were recorded between RPCN and OPCN.

Indexed as

Carcinoma, Renal CellCytoreduction Surgical ProceduresKidney NeoplasmsNephrectomyPostoperative ComplicationsRobotic Surgical ProceduresAgedFemaleHospital MortalityHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesTreatment OutcomeAdverse in-hospital outcomesMetastatic renal cell carcinomaPartial cytoreductive nephrectomyRobotic versus open surgical approach

Identifiers

PMID41217458
PMCPMC12605386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.